Actuate Therapeutics

Actuate Therapeutics is a clinical-stage biopharmaceutical company developing oncology therapies centered on elraglusib, a selective small-molecule inhibitor of glycogen synthase kinase-3 beta (GSK-3β). Elraglusib is in Phase 2 development for metastatic pancreatic ductal adenocarcinoma, where randomized data published in Nature Medicine showed improved overall survival when combined with gemcitabine/nab-paclitaxel, and in Phase 1/2 development for refractory pediatric malignancies including Ewing sarcoma, neuroblastoma, and pediatric leukemias. The company is also advancing an oral tablet formulation of elraglusib (FDA IND cleared May 2026) and combination research with RAS-targeted therapies. Incorporated in 2015, it is headquartered in Fort Worth, Texas and listed on Nasdaq in August 2024; its Q2 2026 report declared substantial doubt about the company's ability to continue as a going concern.